7

Dyslipidemia, characterized by abnormal lipid profiles, is frequently observed in individuals with chronic obstructive pulmonary disease (COPD). This condition has gained attention due to its potential impact on the progression of COPD and its association with increased cardiovascular morbidity and mortality. The mechanisms linking dyslipidemia to COPD are multifactorial, involving systemic inflammation, oxidative stress, and alterations in lipid metabolism. These changes may exacerbate the underlying pulmonary pathology and contribute to the higher cardiovascular risk seen in COPD patients. This review examines the pathophysiological mechanisms, clinical significance, and potential therapeutic strategies to address dyslipidemia in the context of COPD. Emphasis is placed on the importance of early detection, monitoring of lipid profiles, and the role of lipid-modifying agents in improving patient outcomes.

  • Ўқишлар сони 7
  • Нашр санаси 05-04-2025
  • Мақола тилиIngliz
  • Саҳифалар сони114-120
English

Dyslipidemia, characterized by abnormal lipid profiles, is frequently observed in individuals with chronic obstructive pulmonary disease (COPD). This condition has gained attention due to its potential impact on the progression of COPD and its association with increased cardiovascular morbidity and mortality. The mechanisms linking dyslipidemia to COPD are multifactorial, involving systemic inflammation, oxidative stress, and alterations in lipid metabolism. These changes may exacerbate the underlying pulmonary pathology and contribute to the higher cardiovascular risk seen in COPD patients. This review examines the pathophysiological mechanisms, clinical significance, and potential therapeutic strategies to address dyslipidemia in the context of COPD. Emphasis is placed on the importance of early detection, monitoring of lipid profiles, and the role of lipid-modifying agents in improving patient outcomes.

№ Муаллифнинг исми Лавозими Ташкилот номи
1 Fattakhov R.. Assistant Tashkent Medical Academy
№ Ҳавола номи
1 1.Agusti, A., et al. (2012). "Systemic effects of chronic obstructive pulmonary disease." European Respiratory Journal, 40(5), 1230-1242.2.Burge, S., et al. (2003). "The role of exacerbations in the natural history of chronic obstructive pulmonary disease." Thorax, 58(10), 862-867.3.Dahl, M., et al. (2007). "Comorbidities and COPD." European Respiratory Journal, 29(4), 819-826.4.Faner,R., et al. (2015). "Chronic obstructive pulmonary disease and cardiovascular risk: A systematic review." European Respiratory Journal, 45(4), 963-973.5.Guo, F., et al. (2016). "Triglyceride levels and their relationship with lung function in COPD patients." International Journal of Chronic Obstructive Pulmonary Disease, 11, 719-727.6.GOLD (2023). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease.7.Harrison, S. L., et al. (2013). "Systemic inflammation and its relationship with lipid metabolism in COPD." Chest, 144(5), 1260-1269.8.Liu, Y., et al. (2017). "Dyslipidemia in patients with chronic obstructive pulmonary disease: A review." Journal of Clinical Lipidology, 11(3), 623-630.9.Matsuo, T., et al. (2014). "Oxidative stress and lipid metabolism in chronic obstructive pulmonary disease." Respirology, 19(7), 1020-1027.10.Tashkin, D. P., et al. (2009). "Effect of statins on lung function and systemic inflammation in chronic obstructive pulmonary disease." American Journal of Respiratory and Critical Care Medicine, 179(8), 705-711.11.Tse, L., et al. (2013). "Statins and chronic obstructive pulmonary disease: The potential benefits." Pharmacological Reports, 65(3),779-785.12.Tsiligianni, I. G., et al. (2014). "Dyslipidemia in chronic obstructive pulmonary disease: A systematic review and meta-analysis." International Journal of Chronic Obstructive Pulmonary Disease, 9, 725-734.13.Zhou, Y., et al. (2014). "Systemic inflammation, oxidative stress, and lipid metabolism in COPD: A complex interaction." Chronic Respiratory Disease, 11(2), 103-111.14.Будневский А.В., Овсянников Е.С., Лабжания Н.Б. Сочетание хронической обструктивной болезни легких иметаболического синдрома: патофизиологические иклинические особенности.Терапевтический архив.2017;89(1):123-127.15.ВоронковаО.В., СапринаТ.В., БукрееваЕ.Б., ЗимаА.П. Этиопатогенетические параллели и нерешенные вопросы патогенеза коморбидности хронической обструктивной болезни легких и метаболического синдрома (обзор литературы).Ожирение и метаболизм. 2020;17(3):292-298.https://doi.org/10.14341/omet1237816.Кожевникова С.А., Будневский А.В., Овсянников Е.С., Белов В.Н. Особенности клинического течения и качества жизни пациентов с хронической обструктивной болезнью легких на фоне метаболическогосиндрома // Медицинский вестник Северного Кавказа. -2017. -Т. 12. -No1. -С.20-23.https://doi.org/10.14300/mnnc.2017.1200617.Кузьмина О. Ю. Распространенность метаболического синдрома при пылевых болезнях лёгких //Сб. тр. XVIII Национального Конгресса по болезням органов дыхания. Приложение к Уральскому медицинскому журналу. –2008. –С. 120.18.Кытикова О. Ю. и др. Особенности метаболических нарушений при ремиссии хроническойобструктивной болезни легких с сопутствующей кардиальной патологией //Бюллетень физиологии и патологии дыхания. –2012. –No. 43. –С. 40-43.19.Оспанова Т. С. и др. Особливості ліпідного профілю та кардіогемодинаміки при хронічному обструктивному захворюванню легень та коморбідності. –2019.20.Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a populationbased prevalence study. Lancet 2007;370:741-750. doi:10.1016/s0140-6736(07)61377-421.Cebron Lipovec N, Beijers RJHCG, van den Borst B, et al. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. COPD J Chronic Obstr Pulm Dis. 2016;13(3):399-406.https://doi.org/10.3109/15412555.2016.114073222.Choi HS, Rhee CK, Park YB, et al. Metabolic Syndrome in Early Chronic Obstructive Pulmonary Disease: Gender Differences and Impact on Exacerbation and Medical Costs. Int J Chron ObstructPulmon Dis. 2019;14(1):2873-2883.https://doi.org/10.2147/COPD.S22849723.Isago H. The Association between Dyslipidemia and Pulmonary Diseases //Journal of Atherosclerosis and Thrombosis. –2024. –Т. 31. –No. 9. –С. 1249-1259.24.James BD, Jones A V, Trethewey RE, Evans RA. Obesity and metabolic syndrome in COPD: Is exercise the answer? Chron RespirDis. 2018;15(2):173-181.https://doi.org/10.1177/147997231773629425.Kahnert K. et al. Relationship of hyperlipidemia to comorbidities and lung function in COPD: results of the COSYCONET cohort //PLoS One. –2017. –Т. 12. –No. 5. –С. e0177501.26.Sarkar S. et al. A study on dyslipidemia and its association with body mass index and smoking with or without chronic obstructive pulmonary disease among tribal population attending a teaching hospital in West Bengal state of India //Asian Journal of Medical Sciences. –2022. –Т. 13. –No.11. –С. 115-121.27.Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. Loukides S, ed. Am J Respir Crit Care Med. 2019;199(10):1195-1204.https://doi.org/10.1164/rccm.201810-1860SO28.Vicol C. et al. The lipid profile and biochemical parameters of COPD patients in relation to smoking status //Biomedicines. –2022. –Т. 10. –No. 11. –С. 2936.29.Zubiashvili M. et al. THE SIGNIFICANCE OF CIRCULATING SURFACTANT PROTEIN D AND DYSLIPIDEMIA IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CORONARY HEART DISEASE AND THEIR COMBINATION //Georgian Medical News. –2023. –No. 344. –С. 27-33.30.Caram L.M.O., Ferrari R., Naves C.R. Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD // Jornal Brasileiro de Pneumologia. 2016. DOI: 10.1590/S1806-37562015000000121.31.Jain B., Pasari N., Songra A., Bajpai A. The lipid profile parameter in chronic obstructive pulmonary disease patients and correlation with severity of disease // National Journal of Physiology, Pharmacy and Pharmacology. 2017. URL: https://www.sid.ir/FileServer/JE/NFM50006820170202.32.Kahnert K., Lucke T., Huber R.M., Behr J., Biertz F. Relationship of hyperlipidemia to comorbidities and lung function in COPD: results of the COSYCONET cohort // PLOS One. 2017. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0177501.33.Ospanova T.S., Chernyakova I.O. Features of lipid profile and cardiohemodynamics in chronic obstructive pulmonary disease and comorbidities // CyberLeninka. 2019. URL: https://cyberleninka.ru/article/n/features-of-lipid-profile-and-cardiohemodynamics-in-chronic-obstructive-pulmonary-disease-and-comorbidities.pdf.34.Xuan L., Han F., Gong L., Liu Y., Wan C. Association between chronic obstructive pulmonary disease and serum lipid levels: a meta-analysis // Lipids in Health and Disease. 2018. URL: https://link.springer.com/article/10.1186/s12944-018-0904-4
Кутилмоқда